Literature DB >> 3004637

Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine.

E F Targ, J D Kocsis.   

Abstract

The sciatic nerves of rats were demyelinated by microinjection of lysophosphatidylcholine. A variety of abnormalities such as conduction slowing and block were present. Application of the potassium channel blocker 4-aminopyridine (4-AP) to the lesion site, led to an increase in area of the compound action potential recorded across the site of demyelination. Single axon recordings revealed three types of changes that may account for the 4-AP-induced increase in the compound response. One group showed broadening of the action potential. Other axons showed hyperexcitability following 4-AP, as manifest by spontaneous firing and multiple spike discharge following a single stimulus. In some of the axons studied, 4-AP led to overcoming of conduction block. Although many axons showed increased excitability properties in the presence of 4-AP, the frequency-following ability of the axons was reduced, and the absolute refractory period of the axons was increased. These results indicate that pharmacological blockade of potassium channels with 4-AP not only leads to action potential broadening in demyelinated axons, but to a variety of excitability changes. These heterogeneous effects of 4-AP should be considered in the rationale for its clinical use.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004637     DOI: 10.1016/0006-8993(86)90652-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Multiple interacting sites of ectopic spike electrogenesis in primary sensory neurons.

Authors:  Ron Amir; Jeffery D Kocsis; Marshall Devor
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

2.  Molecular reconstruction of nodes of Ranvier after remyelination by transplanted olfactory ensheathing cells in the demyelinated spinal cord.

Authors:  Masanori Sasaki; Joel A Black; Karen L Lankford; Hajime A Tokuno; Stephen G Waxman; Jeffery D Kocsis
Journal:  J Neurosci       Date:  2006-02-08       Impact factor: 6.167

3.  Age-related molecular reorganization at the node of Ranvier.

Authors:  Jason D Hinman; Alan Peters; Howard Cabral; Douglas L Rosene; William Hollander; Matthew N Rasband; Carmela R Abraham
Journal:  J Comp Neurol       Date:  2006-04-01       Impact factor: 3.215

Review 4.  Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.

Authors:  Riyi Shi; Wenjing Sun
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

5.  A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons.

Authors:  Xiuli Zhao; Zongxiang Tang; Hongkang Zhang; Fidelis E Atianjoh; Jian-Yuan Zhao; Lingli Liang; Wei Wang; Xiaowei Guan; Sheng-Chin Kao; Vinod Tiwari; Yong-Jing Gao; Paul N Hoffman; Hengmi Cui; Min Li; Xinzhong Dong; Yuan-Xiang Tao
Journal:  Nat Neurosci       Date:  2013-06-23       Impact factor: 24.884

Review 6.  Dalfampridine extended release: in multiple sclerosis.

Authors:  Claudine M Chwieduk; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

7.  Nerve growth factor maintains potassium conductance after nerve injury in adult cutaneous afferent dorsal root ganglion neurons.

Authors:  B Everill; J D Kocsis
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

Review 8.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

9.  Action potential refractory period in axonal demyelination: a computer simulation.

Authors:  F N Quandt; F A Davis
Journal:  Biol Cybern       Date:  1992       Impact factor: 2.086

Review 10.  Noncoding RNAs: new players in chronic pain.

Authors:  Brianna Marie Lutz; Alex Bekker; Yuan-Xiang Tao
Journal:  Anesthesiology       Date:  2014-08       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.